<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14507">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00291694</url>
  </required_header>
  <id_info>
    <org_study_id>9118</org_study_id>
    <nct_id>NCT00291694</nct_id>
  </id_info>
  <brief_title>Protocol for Women at Increased Risk of Developing Breast Cancer</brief_title>
  <official_title>A Double-blinded Phase II Study of the Expression of Ki-67/MIB-1 in Women With Hyperplasia of the Breast Randomized to Receive Daily Celecoxib 400 mg BID or Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carol Fabian, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Susan G. Komen Breast Cancer Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the effects of twelve months of celecoxib administration by evaluating breast
      tissue needle aspirations, to determine if cell growth can be slowed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A blind randomized study of celecoxib in women at high risk of developing breast cancer.
      Subjects are to take twelve months of drug/placebo. At baseline and after twelve months
      subjects will have a random periareolar fine needle breast aspiration that will be assessed
      for epithelial cell growth and other markers of risk. Baseline and twelve month serum
      samples will also be assessed for hormones and growth factors which may be associated with
      breast cancer risk. Mammograms at baseline and twelve months will also be assessed for
      breast density changes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2003</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Change in Value of Ki-67</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Markers for Hormones and Growth Factors, Mammographic Breast Density</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral Celecoxib 400 mg twice daily for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched blinded placebo twice daily for 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>celecoxib</intervention_name>
    <description>Celecoxib 400 mg BID</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Celebrex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women who have a high risk of breast cancer

          -  older than 18 years

        Exclusion Criteria:

          -  anticoagulants

          -  marked breast tenderness

          -  pregnant or within twelve months of breast feeding/childbirth
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carol J Fabian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <lastchanged_date>October 30, 2015</lastchanged_date>
  <firstreceived_date>February 10, 2006</firstreceived_date>
  <firstreceived_results_date>June 24, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kansas Medical Center Research Institute</investigator_affiliation>
    <investigator_full_name>Carol Fabian, MD</investigator_full_name>
    <investigator_title>Professor, Director Breast Cancer Prevention Unit</investigator_title>
  </responsible_party>
  <keyword>breast atypia</keyword>
  <keyword>double-blind randomized clinical trial</keyword>
  <keyword>RCT</keyword>
  <keyword>celecoxib</keyword>
  <keyword>COX-2 inhibitor</keyword>
  <keyword>placebo</keyword>
  <keyword>high risk for breast cancer</keyword>
  <keyword>breast epithelial hyperplasia</keyword>
  <keyword>ki-67</keyword>
  <keyword>chemoprevention</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo for 12 months</description>
        </group>
        <group group_id="P2">
          <title>Celecoxib</title>
          <description>Celecoxib for 12 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Celecoxib</title>
          <description>Celecoxib for six months</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo for six months</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="48"/>
                <measurement group_id="B2" value="24"/>
                <measurement group_id="B3" value="72"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="48"/>
                <measurement group_id="B2" value="24"/>
                <measurement group_id="B3" value="72"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="48.7" spread="6.6"/>
                <measurement group_id="B2" value="45.2" spread="8.5"/>
                <measurement group_id="B3" value="47.5" spread="7.4"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="48"/>
                <measurement group_id="B2" value="24"/>
                <measurement group_id="B3" value="72"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="48"/>
                <measurement group_id="B2" value="24"/>
                <measurement group_id="B3" value="72"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Value of Ki-67</title>
        <time_frame>Baseline and 12 months</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="43"/>
                  <measurement group_id="O2" value="21"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in Value of Ki-67</title>
            <units>percentage of cells staining positive</units>
            <param>Median</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-1.2" spread="0.85"/>
                  <measurement group_id="O2" value="-2.0" spread="1.09"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Markers for Hormones and Growth Factors, Mammographic Breast Density</title>
        <time_frame>Baseline and 12 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Celecoxib</title>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="43"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title vocab="CTCae">Dyspepsia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="43"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="43"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="43"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>GI-other</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Rectal bleeding</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="CTCAE">Allergic Reaction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Infection-other</sub_title>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="43"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="43"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>pain-other</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="43"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal-other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Hot Flashes</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Reproductive-other</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Irregular menses</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="43"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmnary-other</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="43"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="43"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title vocab="CTCAE">Skin-other</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Carol Fabian</name_or_title>
      <organization>University of Kansas Medical Center</organization>
      <phone>913-588-3666</phone>
      <email>cfabian@kumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
